None widely established
Evidence Grade E — Very limited evidence. 7 published studies. 0 registered clinical trials.
Alexamorelin is a synthetic growth hormone secretagogue developed in Edinburgh for bowel recovery after abdominal surgery. A Phase II trial produced limited results, and clinical development was discontinued when the developer was acquired in 2008. It has no regulatory approval and is primarily of historical interest.
7 published studies: 7 human, 0 animal, 3 in-vitro, 0 reviews
Alexamorelin has no marketing authorisation. A Phase II trial (approximately 150 patients) for bowel function recovery after abdominal surgery produced limited results. Published controlled efficacy data are minimal. Ardana Biosciences was acquired by Shire in 2008 and the programme was discontinued.
No further clinical development has occurred. The compound is primarily of historical interest within the growth hormone secretagogue research field.
Research suggests alexamorelin activates the ghrelin receptor on both pituitary cells (stimulating growth hormone release) and on nerves in the gut wall (potentially stimulating gut motility). This dual activity was the rationale for developing it for post-operative ileus — a common condition where gut motility stops after abdominal surgery. These proposed mechanisms were not validated in clinical outcomes.
Research suggests a Phase II trial (approximately 150 patients) in post-operative bowel function recovery produced inconclusive results. Published controlled efficacy data are minimal. No further clinical development has occurred since the developer's acquisition. The compound is of limited current relevance. Its dual mechanism — stimulating both growth hormone release and gut motility — was scientifically interesting but was not validated in clinical outcomes.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Somatropin has been available since the mid-1980s and is one of the most established peptide therapies. It is sold under numerous brand names including Genotropin, Humatrope, Norditropin, and Omnitrope (the first biosimilar approved in the US, 2006). Approved indications include childhood and adult growth hormone deficiency, Turner syndrome, children born small for gestational age, Prader-Willi syndrome, idiopathic short stature, and short stature from chronic kidney disease. Daily injection has been the main burden of somatropin therapy, particularly for paediatric patients who may require years of treatment. This has driven the development of once-weekly alternatives (somatrogon and somapacitan), which are gradually changing the treatment landscape. Annual treatment costs remain substantial, and concerns about misuse in anti-ageing and performance enhancement contexts are ongoing.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
